Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes.

Wu T, Bound MJ, Zhao BR, Standfield SD, Bellon M, Jones KL, Horowitz M, Rayner CK.

Diabetes Care. 2013 Jul;36(7):1913-8. doi: 10.2337/dc12-2294. Epub 2013 Jan 28.

2.

The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.

Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL.

Aliment Pharmacol Ther. 2012 Aug;36(4):379-90. doi: 10.1111/j.1365-2036.2012.05198.x. Epub 2012 Jun 28.

3.

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.

Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK.

Endocr Pract. 2013 Jan-Feb;19(1):19-28. doi: 10.4158/EP12100.OR.

PMID:
23186950
4.

[New drugs; exenatide and sitagliptin].

van Bronswijk H, Dubois EA, Pijl H, Cohen AF.

Ned Tijdschr Geneeskd. 2008 Apr 12;152(15):876-9. Review. Dutch.

PMID:
18512528
5.

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.

Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D.

Clin Ther. 2013 Mar;35(3):273-285.e7. doi: 10.1016/j.clinthera.2013.01.010. Epub 2013 Feb 21.

PMID:
23433601
6.

Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.

Thazhath SS, Wu T, Bound MJ, Checklin HL, Standfield S, Jones KL, Horowitz M, Rayner CK.

Am J Clin Nutr. 2016 Jan;103(1):66-70. doi: 10.3945/ajcn.115.117440. Epub 2015 Nov 25.

7.

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.

DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.

Curr Med Res Opin. 2008 Oct;24(10):2943-52. doi: 10.1185/03007990802418851 . Epub 2008 Sep 10.

PMID:
18786299
8.

Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients.

Samocha-Bonet D, Wong O, Synnott EL, Piyaratna N, Douglas A, Gribble FM, Holst JJ, Chisholm DJ, Greenfield JR.

J Nutr. 2011 Jul;141(7):1233-8. doi: 10.3945/jn.111.139824. Epub 2011 May 18.

9.

Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans.

Wu T, Zhao BR, Bound MJ, Checklin HL, Bellon M, Little TJ, Young RL, Jones KL, Horowitz M, Rayner CK.

Am J Clin Nutr. 2012 Jan;95(1):78-83. doi: 10.3945/ajcn.111.021543. Epub 2011 Dec 7.

10.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.

PMID:
16912128
11.
12.
13.

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.

Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.

Diabetes Obes Metab. 2008 Dec;10(12):1212-20. doi: 10.1111/j.1463-1326.2008.00887.x. Epub 2008 May 12.

PMID:
18476982
14.

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.

Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, Terauchi Y.

Acta Diabetol. 2012 Jun;49(3):225-30. doi: 10.1007/s00592-011-0322-9. Epub 2011 Sep 6. Erratum in: Acta Diabetol. 2012 Jun;49(3):231.

PMID:
21898126
15.

Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes.

Ma J, Stevens JE, Cukier K, Maddox AF, Wishart JM, Jones KL, Clifton PM, Horowitz M, Rayner CK.

Diabetes Care. 2009 Sep;32(9):1600-2. doi: 10.2337/dc09-0723. Epub 2009 Jun 18.

16.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
17.

A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.

Wu T, Little TJ, Bound MJ, Borg M, Zhang X, Deacon CF, Horowitz M, Jones KL, Rayner CK.

Diabetes Care. 2016 Apr;39(4):511-7. doi: 10.2337/dc15-2298. Epub 2016 Jan 19.

PMID:
26786576
18.

Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.

Schirra J, Leicht P, Hildebrand P, Beglinger C, Arnold R, Göke B, Katschinski M.

J Endocrinol. 1998 Jan;156(1):177-86.

19.
20.

Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.

Imai C, Saito M, Mochizuki K, Fuchigami M, Goda T, Osonoi T.

Metabolism. 2014 Jun;63(6):746-53. doi: 10.1016/j.metabol.2013.12.014. Epub 2014 Jan 7.

PMID:
24559582

Supplemental Content

Support Center